Sign In
Buy DHR
$178.08
+1.97 (+1.12%)
At Close: Jun 03, 2026
3 Top Value Stocks to Buy and Hold for 2025
11:05am, Tuesday, 11'th Feb 2025
These high-quality companies are solid—and their stocks look cheap.
Where I'd Put $10,000 Right Now - My Best Dividend Picks For Income And Growth
07:30am, Monday, 10'th Feb 2025
I started investing with a modest $4,000, now growing it into a 23-stock portfolio. The median net worth varies by age, but most can invest $10,000 for growth. The goal here isn't to push random picks
Danaher Analysts Cut Their Forecasts After Downbeat Earnings
09:02am, Thursday, 30'th Jan 2025
Danaher Corporation DHR reported weaker-than-expected fourth-quarter earnings on Wednesday.
Danaher Q4 Earnings Miss Estimates, Life Sciences Sales Rise Y/Y
12:54pm, Wednesday, 29'th Jan 2025
DHR's fourth-quarter sales increase 2.1% year over year, benefiting from the solid performance of its Life Sciences and Biotechnology segments.
Danaher (DHR) Reports Q4 Earnings: What Key Metrics Have to Say
12:05pm, Wednesday, 29'th Jan 2025
The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estima
Danaher Corporation (DHR) Q4 2024 Earnings Call Transcript
11:20am, Wednesday, 29'th Jan 2025
Danaher Corporation (DHR) Q4 2024 Earnings Call Transcript
Danaher (DHR) Lags Q4 Earnings Estimates
08:11am, Wednesday, 29'th Jan 2025
Danaher (DHR) came out with quarterly earnings of $2.14 per share, missing the Zacks Consensus Estimate of $2.17 per share. This compares to earnings of $2.09 per share a year ago.
Danaher misses quarterly profit estimates on weak biotech demand
07:02am, Wednesday, 29'th Jan 2025
Danaher on Wednesday missed Wall Street estimates for fourth-quarter profit due to soft demand for tools and services used in drug development by its biotech and pharmaceutical clients.
Danaher Reports Fourth Quarter and Full Year 2024 Results
06:00am, Wednesday, 29'th Jan 2025
WASHINGTON , Jan. 29, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2024. All results in this release reflect only
MARUY vs. DHR: Which Stock Should Value Investors Buy Now?
12:46pm, Tuesday, 28'th Jan 2025
Investors with an interest in Diversified Operations stocks have likely encountered both Marubeni Corp. (MARUY) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
Danaher Gears Up to Post Q4 Earnings: What Lies Ahead for the Stock?
10:31am, Friday, 24'th Jan 2025
DHR's Q4 results are likely to be ailed by weakness in the Biotechnology and Life Sciences segments.
Danaher (DHR) Earnings Expected to Grow: Should You Buy?
11:06am, Wednesday, 22'nd Jan 2025
Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aldevron Unveils Next-Generation Alchemy™ Cell-Free DNA Technology for Research Grade Applications
07:26am, Tuesday, 21'st Jan 2025
FARGO, N.D.--(BUSINESS WIRE)--Aldevron Unveils Next-Generation Alchemy™ Cell-Free DNA Technology for Research Grade Applications.
Danaher: Transition Year Recap
07:46am, Thursday, 16'th Jan 2025
Danaher faced a disappointing 2024, despite beating Q3 expectations, due to unaltered full-year guidance and a significant asset writedown. The company executed a $4.5 billion share buyback, with an a
The Near-Perfect Dividend Portfolio With 10 Sleep-Well-At-Night Gems
07:30am, Thursday, 16'th Jan 2025
In a challenging market marked by uncertainty, building a resilient portfolio is key to long-term financial stability and peace of mind. Sleep-well-at-night, or SWAN, stocks are key. These reliable di
